Gufic Biosciences Q4 FY26: Indore scale-up begins to show in revenue and margins

Q4 FY26 total revenue was 252.1 crore, EBITDA was 44.7 crore (17.73% margin), and PAT was 20.5 crore (8.13% margin).

FY26 total revenue was 940.5 crore, EBITDA was 152.9 crore (16.26% margin), and PAT was 63.2 crore (6.72% margin).

Commercial production commenced in October 2024. Designed capacities are 5 million lyophilized vials per month, 6 million liquid vials per month, and 10 million ampoules per month.

The presentation targets EU GMP and UK MHRA clearance in Q1 FY27, and indicates a US FDA timeline of FY29 with dates triggered by clients for CDMO programs.

The presentation states that at peak utilization (75%+), Indore alone can generate approximately Rs 675 to 700 crore of revenue from domestic and export pull-through.

Sparsh shifted from direct-to-hospital billing to a CFA and stockist-led architecture. The presentation states this reduced debtor days, and compressed revenue by Rs 14 to 16 crore in Q3 FY26 and Rs 3 to 5 crore in Q4 FY26.

The company states it is shifting from distributor-led opportunistic filings to an IP-owned, complex-injectables-led model where Gufic holds marketing authorisations through Gufic Ireland and monetises via direct supply, out-licensing, and tech-transfer fees.